HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 40, 41461-41467, October 1, 2004

This Article Full Text Full Text (PDF) All Versions of this Article: 279/40/41461    most recent M404976200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antonyak, M. A. Articles by Cerione, R. A. Search for Related Content PubMed PubMed Citation Articles by Antonyak, M. A. Articles by Cerione, R. A. Social Bookmarking                      What's this?

Augmentation of Tissue Transglutaminase Expression and Activation by Epidermal Growth Factor Inhibit Doxorubicin-induced Apoptosis in Human Breast Cancer Cells^*

Marc A. Antonyak, Allison M. Miller, Jaclyn M. Jansen, Jason E. Boehm, Cheryl E. Balkman, Joseph J. Wakshlag, Rodney L. Page, and Richard A. Cerione¶

From the Departments of Molecular Medicine and Clinical Sciences, Cornell University, Ithaca, New York 14853

Tissue transglutaminase (TGase) exhibits both a GTP binding/hydrolytic capability and an enzymatic transamidation activity. Increases in TGase expression and activation often occur in response to stimuli that promote cellular differentiation and apoptosis, yet the signaling mechanisms used by these stimuli to regulate TGase expression and activation and the role of TGase in these cellular processes are not well understood. Retinoic acid (RA) consistently induces TGase expression and activation, and it was shown recently that RA-induced TGase expression was inhibited in NIH3T3 mouse fibroblasts co-stimulated with epidermal growth factor (EGF). Here we investigate whether EGF also antagonized RA-induced TGase expression in breast cancer cells. We found that EGF stimulation affected TGase expression and activation very differently in these cancer cells. Not only did EGF fail to block RA-induced TGase expression, but also EGF alone was sufficient to potently up-regulate TGase expression and activation in SKBR3 cells, as well as MDAMB468 and BT-20 cells. Inhibiting phosphoinositide 3-kinase activity severely diminished the ability of EGF and RA to increase TGase protein levels, whereas a constitutively active form of phosphoinositide 3-kinase potentiated the induction of TGase expression by EGF in SKBR3 cells. Because EGF is an established antiapoptotic factor, we examined whether the protection afforded by EGF was dependent on its ability to up-regulate TGase activity in SKBR3 and BT-20 cells. Exposure of cells to a TGase inhibitor or expression of a dominant-negative form of TGase potently inhibited EGF-mediated protection from doxorubicin-induced apoptosis. Moreover, expression of exogenous TGase in SKBR3 cells mimicked the survival advantage of EGF, suggesting that TGase activation is necessary and sufficient for the antiapoptotic properties of EGF. These findings indicate for the first time that EGF can induce TGase expression and activation in human breast cancer cells and that this contributes to their oncogenic potential by promoting chemoresistance.

Received for publication, May 4, 2004 , and in revised form, July 20, 2004.

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed: Dept. of Molecular Medicine, VMC, Cornell University, Ithaca, NY 14853-6401. Tel.: 607-253-3888; Fax: 607-253-3659; E-mail: rac1{at}cornell.edu-email.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Cao, D. N. Petrusca, M. Satpathy, H. Nakshatri, I. Petrache, and D. Matei Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling Carcinogenesis, October 1, 2008; 29(10): 1893 - 1900. [Abstract] [Full Text] [PDF]

				L. Maiuri, A. Luciani, I. Giardino, V. Raia, V. R. Villella, M. D'Apolito, M. Pettoello-Mantovani, S. Guido, C. Ciacci, M. Cimmino, et al. Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPAR{gamma} Down-Regulation J. Immunol., June 1, 2008; 180(11): 7697 - 7705. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF]

				T.-S. Lai, Y. Liu, W. Li, and C. S. Greenberg Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells FASEB J, December 1, 2007; 21(14): 4131 - 4143. [Abstract] [Full Text] [PDF]

				M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase Cancer Res., August 1, 2007; 67(15): 7194 - 7202. [Abstract] [Full Text] [PDF]

				M. A. Antonyak, J. M. Jansen, A. M. Miller, T. K. Ly, M. Endo, and R. A. Cerione Two isoforms of tissue transglutaminase mediate opposing cellular fates PNAS, December 5, 2006; 103(49): 18609 - 18614. [Abstract] [Full Text] [PDF]

				D.-S. Kim, S.-S. Park, B.-H. Nam, I.-H. Kim, and S.-Y. Kim Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and Nuclear Factor-{kappa}B Inactivation. Cancer Res., November 15, 2006; 66(22): 10936 - 10943. [Abstract] [Full Text] [PDF]

				A. P. Mann, A. Verma, G. Sethi, B. Manavathi, H. Wang, J. Y. Fok, A. B. Kunnumakkara, R. Kumar, B. B. Aggarwal, and K. Mehta Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway. Cancer Res., September 1, 2006; 66(17): 8788 - 8795. [Abstract] [Full Text] [PDF]

				J. J. Wakshlag, F. A. Kallfelz, R. R. Wakshlag, and G. M. Davenport The Effects of Branched-Chain Amino Acids on Canine Neoplastic Cell Proliferation and Death J. Nutr., July 1, 2006; 136(7): 2007S - 2010S. [Full Text] [PDF]

				J. Y. Fok, S. Ekmekcioglu, and K. Mehta Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther., June 1, 2006; 5(6): 1493 - 1503. [Abstract] [Full Text] [PDF]

				S. Mishra, A. Saleh, P. S. Espino, J. R. Davie, and L. J. Murphy Phosphorylation of Histones by Tissue Transglutaminase J. Biol. Chem., March 3, 2006; 281(9): 5532 - 5538. [Abstract] [Full Text] [PDF]

				L. Yuan, K. Choi, C. Khosla, X. Zheng, R. Higashikubo, M. R. Chicoine, and K. M. Rich Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas Mol. Cancer Ther., September 1, 2005; 4(9): 1293 - 1302. [Abstract] [Full Text] [PDF]